Image of T lymphocytes (purple) located in different tumour microenvironments....
Image of T lymphocytes (purple) located in different tumour microenvironments. Nearer to blood vessels (cells with blue nuclei) or farther away (unstained cells).

Image credit: UPF

News • New insights on TILs

Immune cells in the tumour microenvironment: Better near than far away?

A study led by Universitat Pompeu Fabra (UPF) on immune cells in the tumour microenvironment describes the relationship between the proximity of lymphocytes to the blood supply and their functional capacity.

The infiltrating lymphocytes found in solid tumours vary according to the microenvironment in which they are found. Proximity to the blood supply – and, therefore, the ability to access nutrients (glucose) and oxygen – determines different functional capabilities of the lymphocytes. This is the main conclusion of a research study conducted at Pompeu Fabra University in collaboration with the Hospital del Mar Research Institute. It found that T lymphocytes located far from the blood supply – which are found in a potentially hostile tumour microenvironment – have distinctive characteristics but retain their functional capacity. This discovery reveals previously unknown aspects of the heterogeneity of T cells, which are key in immunotherapy. 

The study was published in EMBO Reports. 

In tumours, the immune response faces strong opposition from the microenvironment. A better understanding of how the location of lymphocytes within this heterogeneous mass determines their metabolic strengths and vulnerabilities can help develop more effective immunotherapies

José Aramburu

Tumours are abnormal tissue masses that arise when cells multiply excessively or do not die when they should. However, we often forget that these masses are not uniform. They are small ecosystems that contain dozens or even hundreds of different cell types. In addition to cell diversity, tumours are characterized by abnormal vascularization, which creates different microenvironments within the mass where access to nutrients and oxygen varies. 

Tumour-infiltrating lymphocytes (TILs) are immune system cells found within tumours. When TILs are active, they can help destroy tumour cells. Hence the different immunotherapy treatments based on the reactivation of these cells. 

A study by the Immunology Group at Pompeu Fabra University, carried out in collaboration with the B Cell Biology Research Group at the Hospital del Mar Research Institute, reveals the functional and metabolic differences of TILs depending on their access to the blood supply. “Lymphocytes with greater access can obtain nutrients such as glucose more easily and be more active biosynthetically”, asserts José Aramburu, study co-director and member of the UPF Immunology Group. 

According to the study, lymphocytes located in adverse microenvironments –distant from the blood supply– retain their functionality. “Surprisingly, these lymphocytes can achieve substantial activation and might be able to maintain sufficient energy at very low glucose levels”, explains Cristina López-Rodríguez, who also co-led the study. In addition, these T lymphocytes “show a lower expression of immune markers associated with inhibition and exhaustion, which suggests that they could play a different role in the anti-tumour response”, adds López-Rodríguez, who also leads the UPF Immunology Group. 

Beyond the functional and metabolic differences in lymphocytes, this knowledge has potential in the design and improvement of immunotherapy treatments. “In tumours, the immune response faces strong opposition from the microenvironment”, Aramburu states. “A better understanding of how the location of lymphocytes within this heterogeneous mass determines their metabolic strengths and vulnerabilities can help develop more effective immunotherapies”, the researcher concludes. 


Source: Universitat Pompeu Fabra Barcelona 

24.07.2026

Related articles

Photo

News • Focus on tumor STAT1 acetylation

How cancer cells learn under pressure to evade immunotherapy

Immunotherapy has been hailed as a breakthrough in cancer treatment. But new research reveals: under sustained treatment pressure, cancer does not simply weaken — it adapts, learns, and fights back.

Photo

News • Alteration of immune response

Multiple myeloma: dangerous diversity

When multiple myeloma cancer cells break out and multiply outside the bone marrow, a wide variety of tumor cells arise, accompanied by a significantly altered immune response, new research shows.

Photo

News • Researcher reveals vulnerability

New approach to crack persister tumour cells

Persister cells arise as a result of cancer treatment and are often responsible for tumour relapse. Researchers identified a distinctive feature of persister cells, paving the way for new treatments.

Subscribe to Newsletter